Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-003 · Medication safety
MED-RASI-002: RAS inhibitor creatinine change review
RAS inhibitor creatinine change review. Evaluates ACEi or ARB initiated or dose increased is true.
Active rulePriority 103Kidney engine v1.2.0
Condition
- All of:
- ACEi or ARB initiated or dose increased == true
- serum creatinine increase percent within 4 weeks > 30
What it reports
- Medication flag: RASi_change_requires_evaluation
- Message: Creatinine rise >30% within 4 weeks warrants evaluation of AKI, volume status, concomitant medicines and renovascular concern before therapy decision.
Evidence
- R1KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.Supports: CKD definition and chronicity CGA classification albuminuria confirmation risk prediction referral medication stewardship progression monitoring
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.